Efficacy News and Research

RSS

Shire announces results of Vyvanse Phase 2 signal finding study for Major Depressive Disorder

Shire plc the global specialty biopharmaceutical company, today announced results from a Phase 2 signal finding study of Vyvanse(R) [lisdexamfetamine dimesylate (or SPD489)] in patients who have had residual symptoms of depression following treatment with LEXAPRO(escitlopram) for Major Depressive Disorder (MDD).

29 Oct 2010

Researchers analyze how sleep disorders affect risk perception in driving

Within the framework of a recent research project, University of Granada researchers will analyse how sleep disorders affect risk perception in driving. To such purpose, three last-generation simulators provided by the Faculty of Psychology will be employed.

29 Oct 2010

Novel small molecule inhibitors may provide new therapy for colon cancer

Researchers are one step closer to providing a new therapy for colon cancer, after findings revealed that a small molecule focal adhesion kinase (FAK) inhibitor known as Y15 effectively blocked cell viability, promoted detachment and apoptosis, and decreased tumor growth in mice. These findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.

29 Oct 2010

ImmuneRegen's Homspera enhances survival of animals vaccinated with experimental melanoma vaccine

ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR BioSciences Holdings, Inc., today announced that treatment with its lead compound, Homspera®, improved the survival of animals vaccinated with an experimental melanoma vaccine.

29 Oct 2010

Nanomedicine Center for Nucleoprotein Machines receives $16.1 million NIH award

The Georgia Tech-led Nanomedicine Center for Nucleoprotein Machines has received an award of $16.1 million for five years as part of its renewal by the National Institutes of Health (NIH). The eight-institution research team plans to pursue development of a clinically viable gene correction technology for single-gene disorders and demonstrate the technology's efficacy with sickle cell disease.

29 Oct 2010

Coadministration of INTUNIV tablets with stimulant reduces ADHD symptoms

Shire plc the global specialty biopharmaceutical company, today presented research results of once-daily INTUNIV (guanfacine) Extended-Release Tablets, coadministered with stimulants in children and adolescents diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) who had suboptimal response to treatment with a long-acting stimulant alone.

29 Oct 2010

Low levels of pre-treatment radiation do not risk radiotherapy efficacy in prostate, lung cancer patients

Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit will present data that suggests low levels of pre-treatment radiation mimicking the doses delivered by CT scans for image guidance pose no risk to the efficacy of radiotherapy in patients with prostate carcinoma and non-small cell lung carcinoma. The findings will be formally announced on Sunday, Oct. 31, during the American Society of Therapeutic Radiology and Oncology (ASTRO) Annual Meeting.

29 Oct 2010

SPRYCEL receives FDA approval for treating adult patients with Ph+ CML in chronic phase

After receiving a priority review, Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved SPRYCEL (dasatinib) 100 mg once daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.

29 Oct 2010

New approach for early diagnosis of pancreatic cancer

Pancreatic tumors are one of the most lethal cancers, with fewer than five percent of patients surviving five years after diagnosis. But a new study that peers deeply into the genetics of pancreatic cancer presents a bit of good news an opportunity for early diagnosis. In contrast to earlier predictions, many pancreatic tumors are, in fact, slow growing, taking nearly 20 years to become lethal after the first genetic perturbations appear.

29 Oct 2010

Forest, Almirall report topline results from aclidinium bromide comparative Phase III study in COPD

Forest Laboratories, Inc. and Almirall, S.A. today announced top-line results from ACCORD COPD II, a 12-week Phase III study comparing the efficacy and safety of inhaled aclidinium bromide, an investigative bronchodilator, to placebo in 544 patients with moderate to severe COPD.

29 Oct 2010

VIVUS receives FDA CRL for QNEXA NDA

VIVUS, Inc. announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for the investigational new drug QNEXA® (phentermine/topiramate) Controlled-Release Capsules. The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form.

29 Oct 2010

FDA approves Sprycel for treatment of adults with Ph+ CP-CML

The U.S. Food and Drug Administration today approved a new indication for Sprycel (dasatinib) for the treatment of a rare blood cancer when it is first diagnosed. The cancer, called Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML), is a slowly progressing blood and bone marrow disease linked to a genetic abnormality.

29 Oct 2010

StemCells initiates HuCNS-SC second clinical trial for Batten disease in children

StemCells, Inc. announced today that it has initiated a second clinical trial of its HuCNS-SC product candidate (purified human neural stem cells) in neuronal ceroid lipofuscinosis (NCL, also often referred to as Batten disease), a fatal neurodegenerative disorder in children.

29 Oct 2010

Pfizer announces approval of Lyrica capsules for peripheral neuropathic pain

Pfizer Inc announced that the Japanese Ministry of Health, Labour and Welfare approved Lyrica (pregabalin) capsules for the treatment of peripheral neuropathic pain. This follows the recent approval in Japan of Lyrica for the treatment of postherpetic neuralgia on April 16, 2010. Lyrica is the first medication approved for peripheral neuropathic pain in Japan where it is co-promoted with Eisai Co., Ltd.

29 Oct 2010

Geron 2010 third quarter revenue increases from $494,000 to $546,000

Geron Corporation today reported financial results for the three and nine months ended September 30, 2010.

29 Oct 2010

Pain Therapeutics third quarter net loss decreases from $1.3 million to $1.0 million

Pain Therapeutics, Inc. a biopharmaceutical company, today reported financial results for its third quarter of fiscal year 2010.

29 Oct 2010

Neurocrine third quarter revenue increases from $0.7 million to $14.4 million

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended September 30, 2010.

29 Oct 2010

Antigenics third quarter net loss decreases from $10.8 million to $5.9 million

Antigenics Inc. reported today its results for the quarter ended September 30, 2010. The company incurred a net loss attributable to common stockholders of $5.9 million, or $0.06 per share, basic and diluted, for the third quarter of 2010, compared with a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, in the third quarter of 2009.

28 Oct 2010

CCS presents new 2010 Atrial Fibrillation Guidelines

The Canadian Cardiovascular Society (CCS) presented its new 2010 Atrial Fibrillation Guidelines, the first update in six years, at the Canadian Cardiovascular Congress (CCC) in Montreal.

28 Oct 2010

RExpert to discuss latest advancements in musculoskeletal bioengineering at NCKU International Symposium

The 4th International Symposium and Workshop on Virtual Interactive Musculoskeletal System, organized by National Cheng Kung University, Taiwanese Society of Biomechanics and Taiwanese Society of Biomechanics in Sports, is held on October 28th and 29th in International Conference Hall, Kuang-Fu Campus, National Cheng Kung University (NCKU), Tainan, Taiwan,

28 Oct 2010

Efficacy News and Research

Shire announces results of Vyvanse Phase 2 signal finding study for Major Depressive Disorder

Researchers analyze how sleep disorders affect risk perception in driving

Novel small molecule inhibitors may provide new therapy for colon cancer

ImmuneRegen's Homspera enhances survival of animals vaccinated with experimental melanoma vaccine

Nanomedicine Center for Nucleoprotein Machines receives $16.1 million NIH award

Coadministration of INTUNIV tablets with stimulant reduces ADHD symptoms

Low levels of pre-treatment radiation do not risk radiotherapy efficacy in prostate, lung cancer patients

SPRYCEL receives FDA approval for treating adult patients with Ph+ CML in chronic phase

New approach for early diagnosis of pancreatic cancer

Forest, Almirall report topline results from aclidinium bromide comparative Phase III study in COPD

VIVUS receives FDA CRL for QNEXA NDA

FDA approves Sprycel for treatment of adults with Ph+ CP-CML

StemCells initiates HuCNS-SC second clinical trial for Batten disease in children

Pfizer announces approval of Lyrica capsules for peripheral neuropathic pain

Geron 2010 third quarter revenue increases from $494,000 to $546,000

Pain Therapeutics third quarter net loss decreases from $1.3 million to $1.0 million

Neurocrine third quarter revenue increases from $0.7 million to $14.4 million

Antigenics third quarter net loss decreases from $10.8 million to $5.9 million

CCS presents new 2010 Atrial Fibrillation Guidelines

RExpert to discuss latest advancements in musculoskeletal bioengineering at NCKU International Symposium

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News